» Articles » PMID: 17608509

Identification of Differentially Secreted Biomarkers Using LC-MS/MS in Isogenic Cell Lines Representing a Progression of Breast Cancer

Overview
Journal J Proteome Res
Specialty Biochemistry
Date 2007 Jul 5
PMID 17608509
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

Proteins secreted (the secretome) from cancer cells are potentially useful as biomarkers of the disease. Using LC-MS/MS, the secreted proteomes from a series of isogenic breast cancer cell lines varying in aggressiveness were analyzed by mass spectrometry: nontumorigenic MCF10A, premalignant/tumorigenic MCF10AT, tumorigenic/locally invasive MCF10 DCIS.com, and tumorigenic/metastatic MCF 10CA cl. D. Proteomes were obtained from conditioned serum-free media, partially fractionated using a small reverse phase C2 column, and digested with trypsin for analysis by LC-MS/MS, using a method previously shown to give highly enriched secreted proteomes (Mbeunkui et al. J. Proteome Res. 2006, 5, 899-906). The search files produced from five analyses (three separate preparations) were combined for database searching (Mascot) which produced a list of over 250 proteins from each cell line. The aim was to discover highly secreted proteins which changed significantly in abundance corresponding with aggressiveness. The most apparent changes were observed for alpha-1-antichymotrypsin and galectin-3-binding protein which were highly secreted proteins from MCF10 DCIS.com and MCF10CA cl. D, yet undetected in the MCF10A and MCF10AT cell lines. Other proteins showing increasing abundance in the more aggressive cell lines included alpha-1-antitrypsin, cathepsin D, and lysyl oxidase. The S100 proteins, often associated with metastasis, showed variable changes in abundance. While the cytosolic proteins were low (e.g., actin and tubulin), there was significant secretion of proteins often associated with the cytoplasm. These proteins were all predicted as products of nonclassical secretion (SecretomeP, Center for Biological Sequence Analysis). The LC-MS/MS results were verified for five selected proteins by western blot analysis, and the relevance of other significant proteins is discussed. Comparisons with two other aggressive breast cancer cell lines are included. The protein with consistent association with aggressiveness in all lines, and in unrelated cancer cells, was the galectin-3-binding protein which has been associated with breast, prostate, and colon cancer earlier, supporting the approach and findings. This analysis of an isogenic series of cell lines suggests the potential usefulness of the secretome for identifying prospective markers for the early detection and aggressiveness/progression of cancer.

Citing Articles

Advancements in Single-Cell Proteomics and Mass Spectrometry-Based Techniques for Unmasking Cellular Diversity in Triple Negative Breast Cancer.

Nalla L, Kanukolanu A, Yeduvaka M, Gajula S Proteomics Clin Appl. 2024; 19(1):e202400101.

PMID: 39568435 PMC: 11726282. DOI: 10.1002/prca.202400101.


Proteomics-Based Identification of Dysregulated Proteins and Biomarker Discovery in Invasive Ductal Carcinoma, the Most Common Breast Cancer Subtype.

Neagu A, Whitham D, Seymour L, Haaker N, Pelkey I, Darie C Proteomes. 2023; 11(2).

PMID: 37092454 PMC: 10123686. DOI: 10.3390/proteomes11020013.


Integrative, In Silico and Comparative Analysis of Breast Cancer Secretome Highlights Invasive-Ductal-Carcinoma-Grade Progression Biomarkers.

Kastora S, Kounidas G, Speirs V, Masannat Y Cancers (Basel). 2022; 14(16).

PMID: 36010848 PMC: 9406168. DOI: 10.3390/cancers14163854.


Gal-3BP in Viral Infections: An Emerging Role in Severe Acute Respiratory Syndrome Coronavirus 2.

Gallo V, Arienzo A, Iacobelli S, Iacobelli V, Antonini G Int J Mol Sci. 2022; 23(13).

PMID: 35806317 PMC: 9266551. DOI: 10.3390/ijms23137314.


A Novel Approach for the Discovery of Biomarkers of Radiotherapy Response in Breast Cancer.

Meehan J, Gray M, Martinez-Perez C, Kay C, Wills J, Kunkler I J Pers Med. 2021; 11(8).

PMID: 34442440 PMC: 8399231. DOI: 10.3390/jpm11080796.


References
1.
Chawla R, Lawson D, Sarma P, Nixon D, Travis J . Serum alpha-1 proteinase inhibitor in advanced cancer: mass variants and functionally inert forms. Cancer Res. 1987; 47(4):1179-84. View

2.
Uria J, Seiki M, Fueyo A, Lopez-Otin C . Regulation of collagenase-3 expression in human breast carcinomas is mediated by stromal-epithelial cell interactions. Cancer Res. 1997; 57(21):4882-8. View

3.
Kennedy A . Chemopreventive agents: protease inhibitors. Pharmacol Ther. 1998; 78(3):167-209. DOI: 10.1016/s0163-7258(98)00010-2. View

4.
Sherbet G, Lakshmi M . S100A4 (MTS1) calcium binding protein in cancer growth, invasion and metastasis. Anticancer Res. 1998; 18(4A):2415-21. View

5.
Gilles C, Bassuk J, Pulyaeva H, Sage E, Foidart J, Thompson E . SPARC/osteonectin induces matrix metalloproteinase 2 activation in human breast cancer cell lines. Cancer Res. 1998; 58(23):5529-36. View